Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Seagen Inc (NQ: SGEN ) N/A UNCHANGED Last Price Updated: 4:00 PM EST, Dec 13, 2023 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Seagen Inc < Previous 1 2 ... 5 6 7 8 9 10 11 12 13 ... 17 18 Next > JMP Securities Maintains Market Outperform Rating for Seagen: Here's What You Need To Know February 17, 2023 Via Benzinga Why Boston Beer Shares Are Trading Lower By 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session February 16, 2023 Gainers TravelCenters of America Inc. (NASDAQ: TA) shares jumped 70.5% to $84.32 after BP announced it will acquire the company for $86 per share in cash. Via Benzinga Why Seagen Stock Is Soaring Today February 16, 2023 Investors and analysts liked what they heard in the company's Q4 update. Via The Motley Fool Seagen (SGEN) Q4 2022 Earnings Call Transcript February 15, 2023 SGEN earnings call for the period ending December 31, 2022. Via The Motley Fool 8 Analysts Have This to Say About Seagen February 13, 2023 Via Benzinga Analyst Ratings for Seagen January 20, 2023 Via Benzinga Analysts Are Bullish On Seagen's Catalyst-Rich Pipeline, Finding No Problem With No M&A February 16, 2023 Via Benzinga KBR, Twilio, Roku And Other Big Stocks Moving Higher On Thursday February 16, 2023 U.S. stocks traded lower, with the Dow Jones dropping over 250 points on Thursday. Here are some big stocks recording gains in today’s session. Via Benzinga Seattle Genetics' 'Refreshing' Enthusiasm Drives Stock Surge; Alkermes Briefly Breaks Out February 16, 2023 Seattle Genetics' guidance deliberately excludes a looming opportunity for Padcev. Via Investor's Business Daily Pagaya Technologies To Rally Around Over 120%? Here Are 10 Other Analyst Forecasts For Thursday February 16, 2023 Keybanc boosted the price target for Twilio Inc. (NYSE: TWLO) from $77 to $89. Keybanc analyst Thomas Blakey maintained an Overweight rating on the stock. Twilio shares gained 6.4% to close at $66.05... Via Benzinga Seagen Reports Fourth Quarter and Full Year 2022 Financial Results February 15, 2023 From Seagen Inc. Via Business Wire 2 Under-the-Radar Biotech Stocks to Buy in 2023 February 14, 2023 These stocks may soon start turning heads with their revenue growth. Via The Motley Fool Seagen to Highlight Research in Urothelial Cancer at the 2023 American Society of Clinical Oncology Genitourinary Cancers Symposium February 13, 2023 From Seagen Inc. Via Business Wire RH To Rally Over 15%? Here Are 10 Other Analyst Forecasts For Monday February 06, 2023 Citigroup boosted the price target for RH (NYSE: RH) from $305 to $380. Citigroup analyst Steven Zaccone maintained a Buy rating. Hershey shares fell 4% to $330.00 in pre-market trading. Via Benzinga Benzinga's Top Ratings Upgrades, Downgrades For February 6, 2023 February 06, 2023 Via Benzinga February PDUFA Catalysts Biotech Investors Must Know: Sanofi's Bleeding Disorder Drug, Regeneron's Twin Eylea Label Expansions, 3 Delayed Approvals And More January 31, 2023 The year has started well for biopharma companies on the regulatory front, as most decisions handed out during January were positive. The Food and Drug Administration has already cleared four new... Via Benzinga Union Pacific To Rally Over 11%? Here Are 10 Other Analyst Forecasts For Wednesday January 25, 2023 Keybanc raised the price target for Reliance Steel & Aluminum Co. (NYSE: RS) from $225 to $235. Keybanc analyst Philip Gibbs maintained an Overweight rating. Reliance Steel shares fell 0.2% to close at... Via Benzinga Seagen's Tukysa Becomes First FDA-Approved Treatment For HER2-Positive Metastatic Colorectal Cancer January 20, 2023 Via Benzinga Seagen Announces FDA Accelerated Approval of TUKYSA® (tucatinib) in Combination with Trastuzumab for People with Previously Treated RAS Wild-Type, HER2-Positive Metastatic Colorectal Cancer January 19, 2023 From Seagen Inc. Via Business Wire Seagen to Host Conference Call and Webcast Discussion of Fourth Quarter and Full Year 2022 Financial Results on February 15, 2023 January 19, 2023 From Seagen Inc. Via Business Wire Biogen's 2nd Alzheimer's Antibody, BeiGene's Cancer Drug Label Expansion, Adcom Test For Regeneron And More: January PDUFA Catalysts For Biotech Investors December 27, 2022 Biopharma stocks were not immune to the broader market downturn seen for much of 2022. Via Benzinga Have A Look At William Blair's Top Biotech Picks For 2023 December 25, 2022 William Blair & Company's report outlined some key themes and significant trends to monitor while entering 2023, providing its top stock ideas for the upcoming 12-month period. Via Benzinga Seagen to Present at the J.P. Morgan Healthcare Conference December 20, 2022 From Seagen Inc. Via Business Wire Seagen, Astellas and Merck Announce FDA Acceptance of sBLAs for PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for the First-Line Treatment of Certain Patients With Locally Advanced or Metastatic Urothelial Cancer December 20, 2022 From Seagen Inc. Via Business Wire Why Seagen Stock Is Trading Higher During Monday's Session December 12, 2022 Seagen Inc (NASDAQ: SGEN) shares are trading higher by 4.79% to $129.94 by after the company announced results from the Phase 2 clinical trial of ADCETRIS with novel immunotherapy combination in... Via Benzinga Seagen Announces Results from Phase 2 Clinical Trial of ADCETRIS® (brentuximab vedotin) with Novel Immunotherapy Combination in Patients with Advanced- and Early-Stage Classical Hodgkin Lymphoma December 12, 2022 From Seagen Inc. Via Business Wire 2 Growth Stocks to Buy if the Bear Market Continues in 2023 December 01, 2022 These stocks aren't bargain buys just yet, but they could be soon. Via The Motley Fool Research and Development of Advanced Therapeutics for Ovarian Cancer Fueling Hope December 01, 2022 EQNX::TICKER_START (OTCQB:BVAXF),(NASDAQ:CTIC),(NASDAQ:SGEN),(NYSE:MRK),(NASDAQ:IMGN) EQNX::TICKER_END Via FinancialNewsMedia Topics Intellectual Property Exposures Intellectual Property Seagen to Highlight ADCETRIS® (brentuximab vedotin) Clinical Progress at the 2022 American Society of Hematology (ASH) Annual Meeting December 01, 2022 From Seagen Inc. Via Business Wire Imago BioSciences Catapults To Record High On Merck's $1.35 Billion Buyout November 21, 2022 Seagen who? Merck is putting its cash to work buying a smaller biotech company. Via Investor's Business Daily < Previous 1 2 ... 5 6 7 8 9 10 11 12 13 ... 17 18 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
